Therapy Areas: Vaccines
Eurocine Vaccines signs research and collaboration agreement with Redbiotec
15 June 2022 -

Sweden-based Eurocine Vaccines AB announced on Tuesday that it has signed a research and collaboration agreement with Redbiotec AG, a Sweden-based biopharmaceutical company.

The contract grants Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialise vaccine candidates against Herpes Simplex Virus Type 2, HSV-2, based on the technologies developed by Redbiotec. It includes both an mRNA and a protein-based technology, its documentation and patents within the field of HSV-2. Under the agreement, all activities regarding the development, manufacture and commercialisation until an out-licensing agreement with a third party is signed, will be handled and financed by Eurocine Vaccines.

Proceeds from any future out-licensing or granting of rights to third parties shall be shared between Eurocine Vaccines and Redbiotec, based on the project's development stage at which the contact with the third party is signed.